Financing type: underwritten prospectus offering
Gross proceeds: $40.25-million
Offering: 57.5 million listed shares with 28,749,999 warrants
Offering price: 70 cents per listed share
Warrant exercise terms: $1 per listed share for an 18-month period, subject to an acceleration right
Overallotment option: The underwriters may purchase a maximum of 7.5 million listed shares with 3.75 million warrants for overallotment purposes. As of Feb. 27, 2026, such option has expired as all 7.5 million listed shares with 3.75 million warrants have been issued thereunder. All information presented herein includes such exercise.
Commissions in securities: not applicable (commission in cash only to underwriters: Desjardins Securities Inc., BMO Nesbitt Burns Inc. and Stifel Nicolaus Canada Inc.)
Disclosure: Refer to the prospectus dated Feb. 13, 2026, and the company's news releases dated Jan. 28, 2026, Feb. 13, 2026, and Feb. 19, 2026.
© 2026 Canjex Publishing Ltd. All rights reserved.